Melissa Brammer

1.0k total citations
36 papers, 747 citations indexed

About

Melissa Brammer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Melissa Brammer has authored 36 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Melissa Brammer's work include HER2/EGFR in Cancer Research (17 papers), Cancer Treatment and Pharmacology (10 papers) and Advanced Breast Cancer Therapies (8 papers). Melissa Brammer is often cited by papers focused on HER2/EGFR in Cancer Research (17 papers), Cancer Treatment and Pharmacology (10 papers) and Advanced Breast Cancer Therapies (8 papers). Melissa Brammer collaborates with scholars based in United States, United Kingdom and Denmark. Melissa Brammer's co-authors include Deepa Lalla, Hope S. Rugo, Denise A. Yardley, Lisa I. Wang, Musa Mayer, Peter A. Kaufman, Marianne Ulcickas Yood, Debu Tripathy, Mona Shing and Adam Brufsky and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Melissa Brammer

34 papers receiving 732 citations

Peers

Melissa Brammer
Roel J.W. van Kampen Netherlands
Chana Weinstock United States
Meghna Samant United States
A. Chlistalla United Kingdom
R. Asola Finland
Katarzyna Pogoda Poland
Nicholas Goel United States
R. Kokko Finland
Yushen Qian United States
Servando Cardona‐Huerta Mexico
Roel J.W. van Kampen Netherlands
Melissa Brammer
Citations per year, relative to Melissa Brammer Melissa Brammer (= 1×) peers Roel J.W. van Kampen

Countries citing papers authored by Melissa Brammer

Since Specialization
Citations

This map shows the geographic impact of Melissa Brammer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Brammer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Brammer more than expected).

Fields of papers citing papers by Melissa Brammer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Brammer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Brammer. The network helps show where Melissa Brammer may publish in the future.

Co-authorship network of co-authors of Melissa Brammer

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Brammer. A scholar is included among the top collaborators of Melissa Brammer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Brammer. Melissa Brammer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Tao, Laura Chu, Lisa I. Wang, et al.. (2016). Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. Cancer Causes & Control. 27(9). 1127–1138. 47 indexed citations
2.
Garrison, Louis P., Joseph B. Babigumira, Anthony Masaquel, et al.. (2015). The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. Value in Health. 18(4). 541–546. 14 indexed citations
3.
4.
Kaufman, Peter A., Kenneth J. Bloom, Howard A. Burris, et al.. (2014). Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Cancer. 120(17). 2657–2664. 47 indexed citations
5.
Guérin, Annie, Deepa Lalla, Geneviève Gauthier, et al.. (2014). Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis. SpringerPlus. 3(1). 236–236. 4 indexed citations
6.
Parthan, Anju, Laura Becker, Arthur M. Small, et al.. (2014). Health Care Utilization and Costs by Site of Service for Nonmetastatic Breast Cancer Patients Treated with Trastuzumab. Journal of Managed Care Pharmacy. 20(5). 485–493. 6 indexed citations
7.
Hansen, Ryan N., Scott D. Ramsey, Deepa Lalla, et al.. (2014). Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. SpringerPlus. 3(1). 259–259. 24 indexed citations
8.
Hurvitz, Sara A., Annie Guérin, Melissa Brammer, et al.. (2014). Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting. The Oncologist. 19(9). 901–908. 51 indexed citations
9.
Sun, Yuliang, Nandini Dey, Melissa Brammer, Pradip De, & Brian Leyland‐Jones. (2013). Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab-refractory breast cancer model. Cancer Chemotherapy and Pharmacology. 72(4). 733–745. 8 indexed citations
10.
Garrison, Louis P., Deepa Lalla, Melissa Brammer, et al.. (2013). Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status. Cancer. 119(17). 3113–3122. 26 indexed citations
11.
Masaquel, Anthony, Ryan N. Hansen, Scott D. Ramsey, et al.. (2013). The cost of adverse events in metastatic breast cancer in taxane- and capecitabine-based regimens.. Journal of Clinical Oncology. 31(31_suppl). 261–261. 1 indexed citations
12.
Hurvitz, Sara A., Annie Guérin, Melissa Brammer, et al.. (2012). Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies.. Journal of Clinical Oncology. 30(15_suppl). 1037–1037. 2 indexed citations
13.
Brufsky, Adam, Musa Mayer, Hope S. Rugo, et al.. (2011). Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER. Clinical Cancer Research. 17(14). 4834–4843. 283 indexed citations
14.
Griffiths, Robert I., Deepa Lalla, Robert J. Herbert, et al.. (2011). Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab. Cancer Investigation. 29(9). 573–584. 16 indexed citations
15.
Lenihan, Daniel J., et al.. (2011). Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Annals of Oncology. 23(3). 791–800. 93 indexed citations
16.
Guérin, A., et al.. (2011). Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting.. Journal of Clinical Oncology. 29(15_suppl). 602–602. 3 indexed citations
17.
Rugo, Hope S., Melissa Brammer, Fan Zhang, & Deepa Lalla. (2010). Effect of Trastuzumab on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer: Data From Three Clinical Trials. Clinical Breast Cancer. 10(4). 288–293. 15 indexed citations
18.
Danese, Mark D., Deepa Lalla, Melissa Brammer, Quan V. Doan, & Kevin Knopf. (2010). Estimating recurrences prevented from using trastuzumab in HER‐2/neu–positive adjuvant breast cancer in the United States. Cancer. 116(24). 5575–5583. 10 indexed citations
19.
Mohamadzadeh, Mansour, et al.. (2004). Identification of proteases employed by dendritic cells in the processing of protein purified derivative (PPD). PubMed. 2(1). 8–8. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roel J.W. van Kampen Breakdown of academic impact, for papers by Chana Weinstock Breakdown of academic impact, for papers by Meghna Samant Breakdown of academic impact, for papers by A. Chlistalla Breakdown of academic impact, for papers by R. Asola Breakdown of academic impact, for papers by Katarzyna Pogoda Breakdown of academic impact, for papers by Nicholas Goel Breakdown of academic impact, for papers by R. Kokko Breakdown of academic impact, for papers by Yushen Qian Breakdown of academic impact, for papers by Servando Cardona‐Huerta
Rankless by CCL
2026